Testing a Nutritional Supplement for Muscle Preservation During Calorie Restriction in Adults with Overweight
Tests the safety of Redefine, a supplement, in adults with overweight eating fewer calories.
Key facts
- Who runs it
- Nature's Sunshine Products, Inc.
- Where
- Lehi, United StatesSee the site
- Trial code
- Registry title
- Safety and Tolerability of a Nutritional Formula Designed to Aid in Maintenance of Muscle During Periods of Caloric Restriction in Adults
- Status
- Not yet recruiting
- People taking part
- 80 people, planned
- Started
- Apr 2026
- Planned end
- Oct 2026
- Type of study
- Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Redefine
- Placebo
- Record updated
- 5 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 35 to 65 who are taking semaglutide for weight loss and have reached a weekly dose of 1 mg. It tests a nutritional supplement.
- Age
- 35 to 65 years
- Sex
- All sexes can join.
- Disease stage
- Body mass index (BMI) of 25.0-34.9 kg/m2 while taking semaglutide.
- Earlier treatment
- Must be receiving semaglutide for weight loss, now at a weekly dose of 1 mg. Must not be taking diabetes medicines. Must not have used narcotics, anticoagulants or corticosteroids in the last 30 days.
Main reasons for not taking part
- A serious, unstable illness such as heart, liver, kidney or cancer disease
- Known infection with HIV, TB or hepatitis B or C
- Allergy to ingredients in the study products
- Stopping semaglutide treatment
- More than 1 alcoholic drink per day
The registry criteria, word for word
Show all 21 criteriaShow less
Who can take part
- Has been receiving a GLP-1 receptor agonist (semaglutide) treatment for weight loss, and is titrated to start receiving a weekly dose of 1 mg semaglutide (Inclusive)
- Body Mass Index (BMI): At study enrollment (participants that have achieved 1 mg titration), 25.0-34.9 (kg/m2) while receiving a GLP-1 receptor agonist (semaglutide) (inclusive)
- Willing to give written informed consent to participate in the Study
Who cannot take part
- Medical History and Concurrent Diseases:
- POCBP: Not using effective contraception; Medications/Supplements:
- Currently taking any nutritional supplements judged by the study coordinator to negate or camouflage the effects of the Study Products. See below for a brief list of explicitly allowed supplements
- Use of Corticosteroids during the last 30 days; Other Exclusionary Criteria:
- A serious, unstable illness including cardiac, hepatic, renal, gastrointestinal, respiratory, endocrinologic, neurologic, immunologic/rheumatological, or oncological/hematologic disease
- Allergies related to ingredients in Study products
- Known infection with HIV, TB or Hepatitis B or C
- Diabetes medications
- Any sound medical, psychiatric and/or social reason which, in the opinion of the PI, would preclude safe participation in this Study or interfere with compliance
- Explicitly allowed supplements: Fish Oil, Multivitamin, Magnesium, Vitamin D, Vitamin C
- Any concurrent condition (including clinically significant abnormalities in medical history, physical examination, or laboratory evaluations) which, in the opinion of the PI, would preclude safe participation in this study or interfere with compliance
- Discontinuation of semaglutide treatment
- Discontinuation of semaglutide treatment may be necessary in some cases. However, during the titration phase, GLP-1-related symptoms often do not require treatment discontinuation or reinitiation
- Use of Narcotics during the last 30 days
- Use of Anticoagulants during last 30 days
- Use of controlled substances on a recreational basis during the last 30 days
- Consumption of more than 1 alcoholic beverage per day (One beverage is a 5-ounce glass of wine, 12 ounces of beer, or one ounce of hard liquor)
- Inability to comply with Study and/or follow-up visits
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 35 and 65 years old?
Where in United States
- Breakthrough MedicalLehi, United StatesContact: Rustin GibbsNot yet recruiting
About the trial
What the trial wants to find out
Muscle loss during caloric restriction is a significant concern for metabolic health and physical function, yet there is limited evidence on interventions that simultaneously target multiple contributing pathways. This study investigates a multi-component formulation targeting these complementary pathways to address critical gaps in strategies for preserving lean mass during energy restriction. The primary goal of this study is to demonstrate the safety and tolerability of the product Redefine when used as an adjunct to a well-established caloric restriction regimen. Caloric restriction is known to result in unintended loss of skeletal muscle mass, which may negatively impact physical function and metabolic health. This study seeks to evaluate whether supplementation with Redefine may help preserve muscle mass and support the maintenance of healthy muscle function during caloric restriction. Secondarily, this study aims to explore whether Redefine supplementation may confer favorable changes in body composition in subjects participating in a caloric restriction regimen. This product consists of HMB, postbiotics and botanicals.
The 4 groups in the trial
- Redefine for 60 daysTreatment being tested
Participants consume Redefine daily for 60 days
Treatment: Redefine
- Placebo for 60 daysPlacebo, for comparison
Participants consume Placebo daily for 60 days
Treatment: Placebo
- Redefine for 90 daysTreatment being tested
Participants consume Redefine daily for 90 days
Treatment: Redefine
- Placebo for 90 daysPlacebo, for comparison
Participants consume Placebo daily for 90 days
Treatment: Placebo
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- An Adaptive, Randomized, Double-Blind, Placebo-Controlled Clinical Trial Assessing the Safety and Tolerability of Redefine, a Multi-Ingredient Nutritional Formulation Designed to Aid Lean Mass Preservation in Subjects Undergoing Caloric Restriction
- Plain-language title
- Testing a Nutritional Supplement for Muscle Preservation During Calorie Restriction in Adults with OverweightGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Fit questions
- Built from NCT07447843, who can take part
- Record updated
- 5 March 2026